Pharmacological studies in frog sympathetic ganglion: support for the cholinergic monosynaptic hypothesis for slow IPSP mediation.
The slow inhibitory postsynaptic potential (slow IPSP), the slow excitatory postsynaptic potential (slow EPSP), the late slow excitatory postsynaptic potential (late slow EPSP), and the fast excitatory postsynaptic potential/compound action potential (fast EPSP) were recorded from the 9th or 10th paravertebral sympathetic ganglia of bullfrogs (and some Rana pipiens frogs) by the sucrose-gap technique. The adrenergic antagonists phentolamine, dihydroergotamine and propranolol did not show any antagonistic effect on the slow IPSP when used at concentrations of up to 10, 100 and 10 microM, respectively. U-0521 (3',4'-dihydroxy-2-methylpropriophenone, 50 micrograms/ml), a specific inhibitor of catechol-O-methyltransferase, did not show any potentiating effect on the slow IPSP. The cholinesterase inhibitor neostigmine (0.5-1 microM) induced a large increase in the duration and amplitude of slow IPSP. When phentolamine and propranolol at concentrations greater than 10 microM were used the slow IPSP (and all other synaptic potentials) were non-specifically reduced in amplitude by these drugs. The results reported in this paper do not lend any support to the hypothesis that the slow IPSP in frog sympathetic ganglia is mediated by an adrenergic interneuron. The results are consistent with the proposal that the slow IPSP in this ganglion is mediated by a direct action of acetylcholine released from cholinergic preganglionic fibers.
Yavari
P
P
Section on Electrophysiology, National Institute on Alcohol Abuse and Alcoholism, Rockville, MD 20852.
Weight
F F
FF
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002799:Cholinergic Fibers / Q000187:drug effects / Q000502:physiology*; D004087:Dihydroergotamine / Q000494:pharmacology; D004558:Electric Stimulation; D005728:Ganglia, Sympathetic / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D009388:Neostigmine / Q000494:pharmacology; D009433:Neural Inhibition / Q000187:drug effects*; D010646:Phentolamine / Q000494:pharmacology; D011427:Propiophenones / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011892:Rana catesbeiana; D011894:Rana pipiens; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology
D011427:Propiophenones; D009388:Neostigmine; D004087:Dihydroergotamine; C006104:U 0521; D011433:Propranolol; D010646:Phentolamine